BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18989164)

  • 1. Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.
    Dufour C; Da Costa L; Auger N; Jullien M; Bhangoo R; Grill J
    J Pediatr Hematol Oncol; 2008 Nov; 30(11):857-9. PubMed ID: 18989164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
    Su YW; Chang MC; Chiang MF; Hsieh RK
    J Neurooncol; 2005 Feb; 71(3):315-8. PubMed ID: 15735923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
    Sure D; Dunn I; Norden A; Anderson WS
    Clin Neurol Neurosurg; 2010 Oct; 112(8):741-2. PubMed ID: 20434832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature.
    Noronha V; Berliner N; Ballen KK; Lacy J; Kracher J; Baehring J; Henson JW
    Neuro Oncol; 2006 Jul; 8(3):280-3. PubMed ID: 16728498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does addition of temozolomide to whole brain radiotherapy improve outcome in patients with brain metastases?
    Erridge SC; Gregor A
    Nat Clin Pract Oncol; 2005 Apr; 2(4):194-5. PubMed ID: 16264933
    [No Abstract]   [Full Text] [Related]  

  • 6. Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
    Rashidi A; Sorscher SM
    Leuk Lymphoma; 2015; 56(8):2468-9. PubMed ID: 25530344
    [No Abstract]   [Full Text] [Related]  

  • 7. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors.
    Sterba J; Pavelka Z; Slampa P
    Neoplasma; 2002; 49(2):117-20. PubMed ID: 12088104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.
    Singhal N; Selva-Nayagam S; Brown MP
    J Neurooncol; 2007 Nov; 85(2):229-30. PubMed ID: 17530175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal reactivation of hepatitis B with temozolomide.
    Grewal J; Dellinger CA; Yung WK
    N Engl J Med; 2007 Apr; 356(15):1591-2. PubMed ID: 17429098
    [No Abstract]   [Full Text] [Related]  

  • 10. Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
    Weller M
    Onkologie; 2007 Jul; 30(7):350-1. PubMed ID: 17596741
    [No Abstract]   [Full Text] [Related]  

  • 11. Urticarial hypersensitivity reaction caused by temozolomide.
    Pothiawala S; Hsu MY; Yang C; Kesari S; Ibrahimi OA
    J Drugs Dermatol; 2010 Sep; 9(9):1142-4. PubMed ID: 20865848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndrome following therapy for brain tumor--two case reports.
    Sugiyama K; Kurisu K; Arita K; Taniguchi E; Okamura T; Itoh Y; Yamasaki F; Kajiwara Y; Ueda H; Sakai A
    Neurol Med Chir (Tokyo); 2002 Apr; 42(4):170-4. PubMed ID: 12013670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is protracted low-dose temozolomide feasible in glioma patients?
    Wong ET
    Neurology; 2006 Aug; 67(3):543-4; author reply 543-4. PubMed ID: 16894133
    [No Abstract]   [Full Text] [Related]  

  • 14. Temozolomide: too early for definitive conclusions.
    Brown P; Buckner J
    J Clin Oncol; 2003 Oct; 21(19):3710. PubMed ID: 14512412
    [No Abstract]   [Full Text] [Related]  

  • 15. 10 questions about temozolomide and the treatment of brain tumors.
    Pruitt AA; Rosenfeld MR
    Neurologist; 2005 Nov; 11(6):362-5. PubMed ID: 16286879
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
    Wen PY
    J Clin Oncol; 2010 Apr; 28(12):1977-9. PubMed ID: 20308652
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapy-related myelodysplastic syndrome after alkylating agents and platinum-based therapy for malignant melanoma.
    Nin-Asai R; Sawada M; Matsumoto T; Saito S; Yokota K; Akiyama M
    J Dermatol; 2014 Feb; 41(2):178-9. PubMed ID: 24387309
    [No Abstract]   [Full Text] [Related]  

  • 18. Hemorrhagic cystitis as an unexpected adverse reaction to temozolomide: case report.
    Islam R; Isaacson BJ; Zickerman PM; Ratanawong C; Tipping SJ
    Am J Clin Oncol; 2002 Oct; 25(5):513-4. PubMed ID: 12393995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.
    Chua D; Krzakowski M; Chouaid C; Pallotta MG; Martinez JI; Gottfried M; Curran W; Throuvalas N
    Clin Lung Cancer; 2010 May; 11(3):176-81. PubMed ID: 20439193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
    Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
    Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.